Skip to main content

Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Immunic Inc (NASDAQ: IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).

Dr Vitt explains that 467 patients have been enrolled across various sub-indications including primary progressive, secondary active, and non-active secondary progressive MS. He calls it a "great day for the programme." The trial aims to assess the efficacy of IMU-838 and Dr. Vitt highlights the focus on biomarkers, particularly the neurofilament light chain (NFL), a protein indicative of active disease.

Anticipated next steps include an interim analysis set for release this fall, which will examine biomarker benefits for different sub-indications. Dr. Vitt also reflects on what he considers a successful 2023 so far, with positive data emerging from Immunic's colitis maintenance and IMU-856 celiac disease programs.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  267.74
+9.85 (3.82%)
AAPL  352.45
+0.54 (0.15%)
AMD  530.14
+26.73 (5.31%)
BAC  48.91
-0.53 (-1.07%)
GOOG  279.20
+1.60 (0.58%)
META  616.38
-2.49 (-0.40%)
MSFT  508.29
+2.05 (0.40%)
NVDA  150.96
-4.50 (-2.89%)
ORCL  113.89
-1.11 (-0.97%)
TSLA  383.72
+3.61 (0.95%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.